ADMA Biologics Announces Partial Repayment of High Term Loan Credit Facility by Investing.com

Cash on hand was used to repay $30 million of Ares Capital’s senior secured term loan facility

Reduces ADMA the total (EPA:) Debt reaches $75 million, a 29% reduction.

It also supports earnings growth expectations

RAMSEY, NJ and BOCA RATON, FL, Dec. 20, 2024 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: NASDAQ:) (ADMA or the Company), an integrated commercial biopharmaceutical company specializing in the manufacturing, marketing and development of specialty biologics, announced today that it has repaid $30 million of its $62.5 million original secured loan facility with Ares Capital. Following the partial repayment, ADMA reduced its total aggregate debt to $75 million, consisting of a $42.5 million revolving credit facility and $32.5 million now outstanding under the term loan credit facility. Partial repayment was financed using available cash.

“Adma’s organic cash flow has enabled us to repay $30 million of our senior secured credit facility,” said Adam Grossman, President and CEO of ADMA. “The second repayment of our senior secured credit facility within four months reduces our total gross debt by 29%, and is expected to The reduction in interest expenses enhances our earnings growth potential in the immediate future periods and this decision is a testament to our confidence in the sustainable earnings growth and expected continued cash generation that we expect to continue to reduce and improve the ADMA cost of both debts. and capital in the future.

About ADMA Biologicals (ADMA)

ADMA Biologics is an integrated commercial biopharmaceutical company that specializes in the manufacturing, marketing and development of specialty biologics for the treatment of immunocompromised patients at risk of infection and others at risk of developing certain infectious diseases. ADMA currently manufactures and markets three plasma-derived biologics approved by the U.S. Food and Drug Administration (FDA) for the treatment of immunodeficiency and prevention of certain infectious diseases: BIVIGAM ® (human intravenous immunoglobulin) for the treatment of primary admixtures. Immunodeficiency (PI); ASCENIV™ (human intravenous immune globulin, SLRA 10% liquid) for the treatment of PI; and NABI-HB ® (Hepatitis B Immune Globulin, Human) to provide enhanced immunity against hepatitis B virus. ADMA manufactures immune globulin products in an FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its subsidiary ADMA BioCenters, ADMA also serves as an FDA-approved source plasma collector in the United States, which provides blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, commercialize and develop specialty biologics and human immunoglobulins targeted to specialized patient populations for the treatment and prevention of certain infectious diseases and the management of immunocompromised patient populations who have underlying immunodeficiency, or who may be immunocompromised. For other medical reasons. ADMA holds numerous U.S. and foreign patents relating to and including various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

Cautionary note regarding forward-looking statements

This press release contains forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (We or the company). Forward-looking statements include, but are not limited to, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words such as confident, estimate, project, intend, anticipate or target. , expect, or plan, planning, anticipating, believing, will, likely, likely, should, could, might, or, in each case, their negatives, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements about the Company’s future results of operations, including, but not limited to, expectations for growth of the Company’s earnings, cash balance, cost of debt and capital, as well as expected interest rates. To pay off outstanding debts. Actual events or results may differ materially from those described in this news release due to a number of important factors. Existing and prospective holders of securities are cautioned that there can also be no assurance that the forward-looking statements contained in this press release will be accurate. Except to the extent required by applicable laws or rules, ADMA undertakes no obligation to update any forward-looking statements or to announce revisions to any forward-looking statements. Forward-looking statements are subject to numerous risks, uncertainties and other factors that could cause our actual results and the timing of certain events to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to. to the risks and uncertainties described in our filings with the SEC, including our most recent reports on Forms 10-K, 10-Q and 8-K and any amendments thereto.

Investor Relations Contact:
Michel Papanastos
Senior Managing Director, Argot Partners | 212-600-1902 | [email protected]